Bone mineral density testing, and bisphosphonate and oestrogen prescribing associated with depot medroxyprogesterone acetate utilization-The impact of the boxed warning.

Our findings indicate the absence of BST or EST use solely due to DMPA initiation and present alternative explanations. Published research and publicity leading to the final implementation of the boxed warning in 2004 may explain observed trends for BMD testing. The majority of patients who had a BMD test ordered were also receiving bisphosphonates, suggesting high-risk fracture status or appropriate monitoring.